Cite
HARVARD Citation
Chang, I. et al. (2021). Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing. Journal of clinical pharmacology. pp. 339-348. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Chang, I. et al. (2021). Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing. Journal of clinical pharmacology. pp. 339-348. [Online].